




Instance: composition-en-446d079a08d59e4d16270357097325eb
InstanceOf: CompositionUvEpi
Title: "Composition for senshio Package Leaflet"
Description:  "Composition for senshio Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp7e284287dcd3e3e8e4aa7d32ca883438)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - senshio"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Senshio is and what it is used for </li>
<li>What you need to know before you take Senshio </li>
<li>How to take Senshio </li>
<li>Possible side effects </li>
<li>How to store Senshio </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What senshio is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What senshio is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Senshio contains the active substance ospemifene. Ospemifene belongs to a group of medicines that 
do not contain hormones called Selective Estrogen Receptor Modulators (SERMs).  </p>
<p>Senshio is used to treat women with moderate to severe post-menopausal symptoms in and outside 
the vagina, such as itching, dryness, burning and pain during sex (dyspareunia). This is known as 
vulvar and vaginal atrophy. It is caused by a lowering in the levels of the female hormone oestrogen in 
your body. When this happens, the vaginal walls can become thinner. This happens naturally after 
menopause (post-menopause). </p>
<p>Senshio works in a similar way to some of the helpful effects of oestrogen, helping to improve these 
symptoms and the underlying causes of vulvar and vaginal atrophy. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take senshio"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take senshio"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Senshio 
- If you are allergic to ospemifene or any of the other ingredients of this medicine (listed in 
section 6). 
- If you have or have ever had a blood clot in a vein (thrombosis), for example, in your legs (deep 
vein thrombosis), lungs (pulmonary embolism), or eyes (retinal thrombosis). 
- If you have unexplained vaginal bleeding.<br />
- If your doctor thinks you might have breast cancer or you are being treated for breast cancer.<br />
- If your doctor thinks you might have or you are being treated for cancer which is sensitive to 
oestrogens, such as cancer of the womb. 
- If you have excessive thickening of the womb lining, such as endometrial hyperplasia.  </p>
<p>Warnings and precautions<br />
Once you have started on Senshio you should see your doctor for regular check-ups (at least once a 
year). At these check-ups, discuss with your doctor the benefits and risks of continuing with Senshio. </p>
<p>Talk to your doctor or pharmacist before taking Senshio if any of the following apply to you.<br />
- Any of your close relatives has ever had a blood clot in the leg, lung or other organ. 
- You are seriously overweight (BMI &gt;30 kg/m2). 
- You have an autoimmune condition called systemic lupus erythematosus (SLE).<br />
- If you have had a stroke (a cerebrovascular accident), or if your doctor has told you that you are at 
high risk of having one. 
- If you are suffering from any gynaecological illness other than vulvar and vaginal atrophy. 
- If you have had breast cancer.  </p>
<p>While taking Senshio:</p>
<ul>
<li>If you are unable to walk for a long time or are sitting for a long time in the same position because 
of major surgery, injury or illness, it may prevent good blood circulation and may temporarily 
increase your risk of blood clots. You should therefore speak to your doctor immediately. Your 
doctor may recommend that you stop treatment at least 4 to 6 weeks prior to major surgery or 
during a long period of bed rest e.g. injury or illness. Treatment with Senshio can be restarted as 
soon as you regain your mobility and in consultation with your doctor. </li>
<li>If any vaginal bleeding occurs while taking Senshio or soon after you have stopped taking it, you 
should speak to your doctor. </li>
<li>If you experience signs of a blood clot, such as painful swelling and redness of the legs, sudden 
chest pain, difficulty in breathing or a stroke while taking Senshio, stop taking Senshio and see 
a doctor immediately. </li>
</ul>
<p>Children and adolescents 
Do not give this medicine to children or adolescents. This medicine is only intended for use in post-
menopausal women. </p>
<p>Other medicines and Senshio 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines.  </p>
<p>Do not take Senshio with any of these medicines: </p>
<p>Oestrogens. </p>
<p>Any other medicine belonging to the group called SERMs, such as tamoxifen, toremifene, 
bazedoxifene and raloxifene. </p>
<p>Talk to your doctor before taking Senshio with: </p>
<p>Fluconazole (an oral medicine used to treat fungal infections) as this may increase the amount 
of ospemifene in your blood. Your doctor may consider stopping treatment with Senshio while 
you are taking fluconazole. </p>
<p>Any of the following medicines, which may lead to a reduced effect of Senshio: * 
Rifampicin and rifabutin commonly used to treat tuberculosis. * 
Carbamazepine and phenytoin used to treat convulsions/seizures (anticonvulsants). * 
St John s wort, a herbal medicine sometimes used to treat depression.  * 
Orlistat sometimes used to treat obesity.  </p>
<p>Any of the following medicines, as their concentrations may be increased while taking Senshio: * 
Metformin used to treat Type II diabetes. * 
Aciclovir used to treat cold sores and genital herpes. * 
Ganciclovir used to treat infections caused by a virus called cytomegalovirus. * 
Oxaliplatin, an anti-cancer medicine for advanced (metastatic) cancer of the large bowel 
(colon) or back passage (rectum). </p>
<p>Pregnancy, breast-feeding and fertility 
Senshio is for use only in postmenopausal women. It must not be taken by women who are pregnant, 
who could still have a baby or are breast-feeding. This is because there are no data on the use of 
Senshio in pregnant or pre-menopausal women or those who are breast-feeding. </p>
<p>Tell your doctor immediately if you become pregnant while taking Senshio; treatment should be 
stopped immediately. </p>
<p>Driving and using machines 
Senshio has no known or very little influence on the ability to drive and use machines. </p>
<p>Senshio contains lactose 
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor 
before taking this medicine. 
Senshio contains sodium 
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially  sodium-
free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take senshio"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take senshio"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor 
or pharmacist if you are not sure. </p>
<p>The recommended dose is one tablet taken orally at the same time each day. Senshio should be taken 
with food. The tablets should be swallowed whole with food.  </p>
<p>Senshio must be taken every day for as long as your doctor tells you to. </p>
<p>Patients with liver disease 
This medicine is not recommended if you have severely reduced liver function.  </p>
<p>If you take more Senshio than you should 
If you take more tablets than you should, tell your doctor or pharmacist. </p>
<p>If you forget to take Senshio 
If you forget to take a tablet you should take the missed tablet (with food) as soon as you remember 
within the same day. Do not take two tablets in one day to make up for a forgotten tablet. </p>
<p>If you stop using Senshio 
You will not benefit from the effects of Senshio if you stop using it without talking to your doctor. 
Your doctor will explain the effects of stopping treatment and will also discuss other possibilities for 
treatment with you. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Common side effects (may affect up to 1 in 10 people):</p>
<ul>
<li>An infection of the genitals caused by a fungus (thrush) </li>
<li>Hot flushes </li>
<li>Muscle cramps </li>
<li>Vaginal or genital discharge </li>
<li>Rash </li>
<li>Headache </li>
<li>Vaginal bleeding </li>
</ul>
<p>Uncommon side effects (may affect up to 1 in 100 people):</p>
<ul>
<li>Thickening of the womb lining (endometrium) as seen on ultrasound scan (endometrial 
hypertrophy). </li>
<li>An allergic reaction. Symptoms of an allergic reaction may include rash, itchy skin, raised patches 
on your skin (urticaria), swelling of the tongue and throat that may cause difficulty in breathing 
or swallowing. </li>
</ul>
<p>Reporting of side effects<br />
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store senshio"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store senshio"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and blister after  EXP . 
The expiry date refers to the last day of that month. </p>
<p>This medicine does not require any special storage conditions. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Senshio contains<br />
- The active substance is ospemifene. Each film-coated tablet contains 60 mg ospemifene. 
- The other ingredients are: 
Tablet core: Colloidal silicon dioxide (E 551), magnesium stearate (E 578), mannitol (E 421), 
microcrystalline cellulose (E 460), povidone (E 1201),  regelatinized starch 
(maize), sodium starch glycolate (type A). 
Film coating: Hypromellose (E 464), lactose monohydrate, titanium dioxide (E 171), triacetin 
(E 1518), polyethylene glycol (E 1521). </p>
<p>What Senshio looks like and contents of the pack 
Senshio tablets are oval biconvex, white to off-white, film-coated tablets (approximately 12 mm long 
by 6.45 mm wide) debossed with  60  on one side.<br />
They are packed in blisters and are available in pack sizes of 7, 28 or 84 film-coated tablets.  </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder 
Shionogi B.V. 
Herengracht 1017 CA Amsterdam 
Netherlands </p>
<p>Manufacturer 
Shionogi B.V. 
Herengracht 1017 CA Amsterdam 
Netherlands </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>AT, BE, BG, CY, CZ, DK, EE, IE, EL, FI,  HR, HU, IE, IS, 
LT, LU, LV, MT, NL, NO, PL, RO, SE, SI, SK 
Shionogi B.V. 
Tel/Tel./Te ./Tlf/T l/Puh/S mi/ : 
+ 31 (0)20 491 7contact@shionogi.eu 
DE 
Shionogi GmbH 
Tel: +49 (0) 30 2062980 kontakt@shionogi.eu </p>
<p>ES 
Shionogi SLU 
Tel: +34 911 239 contacta@shionogi.eu </p>
<p>IT 
Shionogi Srl 
Tel: +39 06 94 805 contattaci@shionogi.eu </p>
<p>PT 
Lifewell Pharmaceutical &amp; Healthcare, Lda. 
Tel: +351215810info@lifewell.pt </p>
<p>UK (NI) 
Shionogi B.V. 
Tel +44 (0) 2891248contact@shionogi.eu </p>
<p>FR 
Shionogi SAS 
Tel: +33 (0) 186655contactfrance@shionogi.eu </p>
<p>This leaflet was last revised in </p>
<p>Other sources of information 
Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-446d079a08d59e4d16270357097325eb
InstanceOf: CompositionUvEpi
Title: "Composition for senshio Package Leaflet"
Description:  "Composition for senshio Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp7e284287dcd3e3e8e4aa7d32ca883438)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - senshio"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse </li>
<li>Det skal du vide, før du begynder at tage Senshio </li>
<li>Sådan skal du tage Senshio </li>
<li>Bivirkninger </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What senshio is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What senshio is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Senshio indeholder det aktive stof ospemifen. Ospemifen tilhører en gruppe lægemidler, som ikke 
indeholder hormoner, og som kaldes selektive østrogen-receptor-modulatorer (SERM'er). </p>
<p>Senshio bruges til at behandle kvinder med moderate til svære postmenopausale symptomer i og 
omkring skeden, som f.eks. kløe, tørhed, brændende fornemmelse og smerter ved samleje 
(dyspareuni). Dette kaldes atrofi af vulva og vagina. Det skyldes det faldende niveau af det kvindelige 
kønshormon østrogen i din krop. Når dette sker, bliver slimhinden i skeden tyndere. Dette forekommer 
naturligt efter overgangsalderen (post-menopause). </p>
<p>Senshio virker på en måde, som minder om østrogens gavnlige virkning, ved at det er med til at lindre 
disse gener og underliggende årsager til atrofi af vulva og vagina. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take senshio"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take senshio"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Senshio 
- Hvis du er allergisk over for ospemifen eller et af de øvrige indholdsstoffer i Senshio (angivet i 
afsnit 6). 
- Hvis du har eller nogensinde har haft en blodprop i en vene (trombose), f.eks. i dine ben (dyb 
venetrombose), lunger (lungeemboli) eller øjne (retinal trombose). 
- Hvis du har uforklarlig blødning fra skeden. 
- Hvis din læge mener, at du kunne have brystkræft, eller du er i behandling for brystkræft. 
- Hvis din læge mener, at du kunne have, eller du er i behandling for kræft, som er følsom over for 
østrogener, som f.eks. livmoderkræft. 
- Hvis din livmoderslimhinde er væsentligt fortykket, som f.eks. ved endometriehypertrofi. </p>
<p>Advarsler og forsigtighedsregler </p>
<p>Når du er startet på Senshio, skal du møde op hos lægen til regelmæssige kontroller (mindst en gang 
om året). Ved disse kontroller kan du tale med lægen om fordele og risici ved at fortsætte med 
Senshio. </p>
<p>Kontakt lægen eller apotekspersonalet, før du tager Senshio, hvis et eller flere af nedenstående 
punkter gælder dig. 
- Et nært familiemedlem har haft en blodprop i benet, lungerne eller andet organ. 
- Du er svært overvægtig (BMI &gt;30 kg/m2). 
- Du har en sygdom i immunsystemet, der kaldes systemisk lupus erythematosus (SLE). 
- Hvis du har haft et slagtilfælde, eller hvis din læge har fortalt dig, at du har høj risiko for at få 
et. 
- Hvis du lider af andre gynækologiske sygdomme (ud over atrofi af vulva og vagina). 
- Hvis du har haft brystkræft. </p>
<p>Mens du tager Senshio:</p>
<ul>
<li>Hvis du ikke er i stand til at gå i længere tid, eller du sidder ned i længere tid ad gangen i samme 
stilling på grund af en større operation, skade eller sygdom, kan det forhindre god 
blodcirkulation, og det kan midlertidigt øge risikoen for blodpropper. Du bør derfor straks tale 
med din læge. Din læge vil muligvis anbefale dig at standse din behandling i mindst 4 til 6 uger 
før en større operation eller ved længere tids sengeligning som følge af en skade eller sygdom. 
Behandling med Senshio kan påbegyndes igen, så snart du får din mobilitet tilbage og efter 
aftale med din læge.  </li>
<li>Hvis du bløder fra skeden, mens du tager Senshio eller kort tid efter, at du er holdt op med at 
tage det, skal du kontakte din læge. </li>
<li>Hvis du får tegn på en blodprop, som f.eks. smertefuld hævelse og rødme i benet, pludselige 
smerter i brystet, vejtrækningsbesvær eller et slagtilfælde, mens du tager Senshio, skal du 
straks holde op med at tage Senshio og kontakte en læge. </li>
</ul>
<p>Børn og unge 
Denne medicin må ikke gives til børn eller unge. Dette lægemiddel er kun beregnet til kvinder efter 
overgangsalderen. </p>
<p>Brug af anden medicin sammen med Senshio 
Fortæl altid lægen eller apotekspersonalet, hvis du tager anden medicin, for nylig har taget anden 
medicin eller planlægger at tage anden medicin. </p>
<p>Tag ikke Senshio sammen med nogen af disse lægemidler: 
 
Østrogener. 
 
Alle andre lægemidler, som tilhører gruppen SERM'er (selektive østrogen-receptor-
modulatorer), som f.eks. tamoxifen, toremifen, bazedoxifen og raloxifen. </p>
<p>Kontakt lægen, før du tager Senshio sammen med: 
 
Fluconazol (en medicin, som tages gennem munden, og som bruges til behandling af 
svampeinfektion), da dette kan øge mængden af ospemifen i dit blod. Din læge kan overveje at 
stoppe behandlingen med Senshio, mens du tager fluconazol. 
 
Nogen af følgende lægemidler, da de kan medføre nedsat virkning af Senshio: * 
Rifampicin og rifabutin, som almindeligvis bruges til behandling af tuberkulose. * 
Carbamazepin og phenytoin, som bruges til behandling af kramper/krampetrækninger 
(antiepileptika). * 
Prikbladet perikon (St Johns wort), et naturlægemiddel, som somme tider bruges til 
behandling af depression. * 
Orlistat, som somme tider bruges til behandling af overvægt.<br />
 
Nogen af følgende lægemidler, da koncentrationen af disse kan øges, når du tager Senshio: * 
Metformin, som bruges til behandling af type II-diabetes. * 
Aciclovir, som bruges til behandling af forkølelsessår og herpes på kønsdelene. * 
Ganciclovir, som bruges til behandling af infektioner, som skyldes en virus, der kaldes 
cytomegalovirus. 
 * 
Oxaliplatin, som bruges til behandling af fremskreden (metastaserende) tyktarmskræft 
(kolon) eller endetarmskræft (rektum). </p>
<p>Graviditet, amning og frugtbarhed 
Senshio er kun beregnet til brug til postmenopausale kvinder. Det må ikke tages af kvinder, som er 
gravide, som stadig kan få børn eller ammer. Det skyldes, at der ikke findes data for anvendelse af 
Senshio til gravide eller præmenopausale kvinder eller kvinder, som ammer. </p>
<p>Fortæl det straks til lægen, hvis du bliver gravid, mens du tager Senshio. Behandlingen skal straks 
stoppes. </p>
<p>Trafik- og arbejdssikkerhed 
Senshio har ingen kendt eller en meget lille påvirkning på evnen til at føre motorkøretøj og betjene 
maskiner. </p>
<p>Senshio indeholder lactose 
Kontakt lægen, før du tager dette lægemiddel, hvis lægen har fortalt dig, at du ikke tåler visse 
sukkerarter. </p>
<p>Senshio indeholder natrium 
Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. tablet, dvs. det er i det 
væsentlige natrium-frit. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take senshio"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take senshio"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er du i tvivl, så spørg 
lægen eller apotekspersonalet. </p>
<p>Den anbefalede dosis er én tablet, som tages gennem munden på samme tidspunkt hver dag. Senshio 
skal tages i forbindelse med et måltid. Tabletterne skal synkes hele sammen med mad. </p>
<p>Senshio skal tages hver dag, så længe din læge har ordineret det. </p>
<p>Patienter med leversygdom 
Du bør ikke tage denne medicin, hvis du har alvorligt nedsat leverfunktion. </p>
<p>Hvis du har taget for meget Senshio 
Kontakt lægen eller apotekspersonalet, hvis du har taget for mange tabletter. </p>
<p>Hvis du har glemt at tage Senshio 
Hvis du har glemt at tage en tablet, skal du tage den glemte tablet (i forbindelse med et måltid), så 
snart du husker det samme dag. Du må ikke tage to tabletter på én dag som erstatning for den glemte 
tablet. </p>
<p>Hvis du holder op med at bruge Senshio 
Du vil ikke drage fordel af virkningen af Senshio, hvis du holder op med at tage det uden først at have 
talt med din læge. Din læge vil forklare virkningen af at stoppe behandlingen og kan også drøfte andre 
behandlingstilbud med dig. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 patienter):</p>
<ul>
<li>Betændelse i skeden, som skyldes svamp (vaginal trøske) </li>
<li>Hedestigninger </li>
<li>Muskelkramper </li>
<li>Udflåd fra skeden </li>
<li>Udslæt </li>
<li>Hovedpine </li>
<li>Blødning fra skeden </li>
</ul>
<p>Ikke almindelige bivirkninger (kan forekomme hos op til 1 ud af 100 patienter):</p>
<ul>
<li>Fortykket livmoderslimhinde (endometrium) konstateret ved ultralydsscanning (hypertrofisk 
endometrium). </li>
<li>En allergisk reaktion. Symptomer på en allergisk reaktion kan inkludere udslæt, kløe, hævelser i 
huden (urticaria), hævelser i tunge eller hals, som kan forårsage vejtræknings- eller synkebesvær. </li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge eller apoteket. Dette gælder også mulige 
bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også indberette 
bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendix V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om 
sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store senshio"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store senshio"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på æsken eller blisteren efter "EXP". 
Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen.  </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden.  </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Senshio indeholder:</p>
<ul>
<li>Aktivt stof: ospemifen. Hver filmovertrukket tablet indeholder 60 mg ospemifen. </li>
<li>Øvrige indholdsstoffer: 
Tabletkerne:<br />
Kolloid siliciumdioxid (E551), magnesiumstearat (E578), mannitol (E421), 
mikrokrystallinsk cellulose (E460), povidon (E1201), prægelatiniseret stivelse 
(majs), natriumstivelsesglykolat (type A). 
Filmovertræk:  Hypromellose (E464), lactosemonohydrat, titandioxid (E171), triacetin 
(E1518), polyethylenglykol (E1521). </li>
</ul>
<p>Udseende og pakningsstørrelser 
Senshio tabletter er ovale, bikonvekse, mathvide, filmovertrukne tabletter (ca. 12 mm lang gange 
6,45 mm bred), der er præget med "60" på den ene side. 
De er pakket i blistre og fås i pakningsstørrelser på 7, 28 eller 84 filmovertrukne tabletter. </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen 
Shionogi B.V. 
Herengracht 1017 CA Amsterdam 
Nederlandene </p>
<p>Fremstiller 
Shionogi B.V. 
Herengracht 1017 CA Amsterdam 
Nederlandene </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>AT, BE, BG, CY, CZ, DK, EE, IE, EL, FI, HR, HU, IE, IS, 
LT, LU, LV, MT, NL, NO, PL, RO, SE, SI, SK 
Shionogi B.V. 
Tel/Tel./Teл./Tlf/Tél/Puh/Sími/Τηλ: 
+ 31 (0)20 491 7contact@shionogi.eu 
DE 
Shionogi GmbH 
Tel: +49 (0) 30 2062980 kontakt@shionogi.eu </p>
<p>ES 
Shionogi SLU 
Tel: +34 911 239 contacta@shionogi.eu </p>
<p>IT 
Shionogi Srl 
Tel: +39 06 94 805 contattaci@shionogi.eu </p>
<p>PT 
Lifewell Pharmaceutical &amp; Healthcare, Lda. 
Tel: +351215810info@lifewell.pt </p>
<p>UK (Northern Ireland) 
Shionogi B.V. 
Tel +44 (0) 2891248contact@shionogi.eu </p>
<p>FR 
Shionogi SAS 
Tel: +33 (0) 186655contactfrance@shionogi.eu </p>
<p>Denne indlægsseddel blev senest ændret </p>
<p>Andre informationskilder 
Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-446d079a08d59e4d16270357097325eb
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for senshio Package Leaflet for language en"
Description: "ePI document Bundle for senshio Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-446d079a08d59e4d16270357097325eb"
* entry[0].resource = composition-en-446d079a08d59e4d16270357097325eb

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp446d079a08d59e4d16270357097325eb"
* entry[=].resource = mp446d079a08d59e4d16270357097325eb
                            
                    
Instance: bundlepackageleaflet-da-446d079a08d59e4d16270357097325eb
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for senshio Package Leaflet for language da"
Description: "ePI document Bundle for senshio Package Leaflet for language da"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-446d079a08d59e4d16270357097325eb"
* entry[0].resource = composition-da-446d079a08d59e4d16270357097325eb

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp446d079a08d59e4d16270357097325eb"
* entry[=].resource = mp446d079a08d59e4d16270357097325eb
                            
                    



Instance: mp446d079a08d59e4d16270357097325eb
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product senshio"
Description: "senshio"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "13"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "Senshio is indicated for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy"


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "senshio"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"




RuleSet: 446d079a08d59e4d16270357097325ebListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "senshio"

* status = #current
* mode = #working

* title = "List of all ePIs associated with senshio"

* subject = Reference(mp7e284287dcd3e3e8e4aa7d32ca883438)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#senshio "senshio"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-446d079a08d59e4d16270357097325eb) // senshio en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-446d079a08d59e4d16270357097325eb) // senshio da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-446d079a08d59e4d16270357097325eb
InstanceOf: List

* insert 446d079a08d59e4d16270357097325ebListRuleset
    